Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects

Pharmacogenetics

Volumn 11, Issue 1, 2001, Pages 7-20

  Vaziri, S A J ^a   Hughes, N C ^a   Sampson, H ^a   Darlington, G ^a   Jewett, M A S ^a   Grant, D M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Arylamines; Bioactivation; Bladder cancer; N acetyltransferase

Indexed keywords

2 NAPHTHYLAMINE; 4 BIPHENYLAMINE; AMINOSALICYLIC ACID; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CARCINOGEN; CYTOCHROME P450 1A2; NEMASOL; WAKEUPS;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; BIOTRANSFORMATION; BLADDER CANCER; BLADDER EPITHELIUM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING;

ACETYLTRANSFERASES; ADULT; AGED; AGED, 80 AND OVER; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CARCINOGENS; CARCINOMA, TRANSITIONAL CELL; CYTOCHROME P-450 CYP1A2; ENZYME ACTIVATION; FEMALE; GENOTYPE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0035132712     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200102000-00002     Document Type: Article

References (73)

1. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder
2. Factors involved in the induction of urinary bladder cancer by aromatic amines
3. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT1* 10 allele with higher N-acetylation activity in bladder and colon tissue
4. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer
5. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
6. The procarcinogen hypothesis for bladder cancer: Activities of individual drug metabolizing enzymes as risk factors
7. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: A case-control study
8. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk
9. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1)
10. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560 A mutations
11. PA (P450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines
12. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
13. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochromes(s) P-450 in human liver microsomes
14. A urinary metabolic ratio that reflects systemic caffeine clearance
15. Cancer genes: Single and susceptibility: Exposing the difference
16. The role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer
17. Epidemiology and etiology of bladder cancer
18. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations
19. 64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis
20. Genetic metabolic polymorphisms and the risk of cancer: A review of the literature
21. 68 in the catalytic mechanism of polymorphic human NAT2
22. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2: Functional analysis of NAT1/NAT2 protein chimeras expressed in E. coli
23. Acetyl transferase-mediated metabolic activation of N-hydroxy-4-aminobiphenyl by human uroepithelial cells
24. Inhibitory effect of grapefruit juice and the active component naringenin on CYP1A2 dependent metabolism of caffeine in man
25. A simple test for acetylator phenotype using caffeine
26. Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes
27. Human acetyltransferase polymorphisms
28. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes
29. Metabolic activation of carcinogens
30. N-acetyltransferases, O-acetyltransferases, and N, O-acetyltransferases: Enzymology and bioactivation
31. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers
32. Acetyltransferases and susceptibility to chemicals
33. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases
34. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases
35. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific NAT2 nucleic acid substitutions
36. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers
37. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo/in-vitro probe
38. Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations
39. Inducibility of human cytochromes P-450 primarily involved in the activation of chemical carcinogens
40. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis
41. Role of microsomal cytochromes P450 and prostaglandin H synthase in 4-aminobiphenyl-DNA-adduct formation
42. Polymorphisms for aromatic amine metabolism in humans: Relevance for human carcinogenesis
43. Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosol
44. Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients
45. Metabolism of aromatic amines: Relationships of N-acetylation, O-acetylation, N, O-acetyltransfer and deacetylation in human liver and bladder
46. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas
47. Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction restriction fragment-single strand conformation polymorphism assay
48. N-acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology
49. Drugs used in the chemotherapy of tuberculosis and leprosy
50. NAT2 slow acetylation and bladder cancer risk: A meta-analysis of 22 case-control studies conducted in the general population
51. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: A case-series meta-analysis of a gene-environment interaction
52. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization
53. Sulfation of carcinogenic aromatic hydroxylamines and hydroxamic acids by rat and human sulfotransferases: Substrate specificity, developmental aspects and sex differences
54. A simple salting out procedure for extracting DNA from human nucleated cells
55. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: The influence of smoking
56. Glucuronidation of carcinogenic arylamines and their N-hydroxy derivatives by rat and human phenol UDP-glucuronosyl-transferases of the UGT1 gene complex
57. Genotyping human arylamine N-acetyltransferase type 1 (NAT1). The identification of two novel allelic variants
58. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas
59. Blasengeschwuelste bei fuchsin-arbeitern
60. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer
61. Expression of CYP1A1 and CYP1A2 genes in human liver
62. Epidemiology of bladder cancer
63. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder
64. Metabolism and nucleic acid binding of N-hydroxy-4-acetylaminobiphenyl and N-acetoxy-4-acetylaminobiphenyl by cultured human uroepithelial cells
65. International collaborative study on genetic susceptibility to environmental carcinogens
66. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: Evidence of a gene-gene-exposure three-way interaction
67. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus
68. Epidemiological models of carcinogenesis: The example of bladder cancer
69. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood
70. Metabolic activation of heterocyclic aromatic amines catalysed by human arylamine N-acetyltransferase isozymes (NAT1 and NAT2) expressed in Salmonella typhimurium
71. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues
72. Relationship between NAT1 genotype and phenotype in a Japanese population
73. Arachidonic acid metabolism by human urothelial cells: Implications in aromatic amine-induced bladder cancer